Top Markets
Coin of the day
SynAct Pharma AB SynAct Pharma AB

SynAct Pharma AB

SYNACT
Rangering i aksjer #20988
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS,... SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Aksjekurs
$2.22
Sist synkronisert: 2026-08-21
Markedsverdi
$117.70M
Endring (1 dag)
2.69%
Endring (1 år)
17.26%
Land
SE
Handel SynAct Pharma AB (SYNACT)

Kategori

P/B-forhold for SynAct Pharma AB (SYNACT)
P/B-forhold per 2026 TTM: 0
Ifølge SynAct Pharma AB sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for SynAct Pharma AB fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH